-- 尽管周末中东和平谈判再次取消,生物燃料原料期货周一收高,其中大豆期货领涨农作物期货市场。 芝加哥期货交易所(CBOT)7月大豆期货合约收盘上涨1.15%,报每蒲式耳11.92美元;CBOT 7月豆油期货合约收盘上涨0.48%,报每磅71.67美分。 周一,纽约商品交易所(Nymex)6月乙醇期货合约收盘上涨1.66%,报每加仑1.99美元。 DTN分析师雷特·蒙哥马利表示,大豆市场并未受到美伊和平谈判停滞的影响。 蒙哥马利在每日报告中表示:“豆粕期货周一大幅上涨,这可能是价差交易的结果。迄今为止,豆油在2026年之前的压榨价值中占据了历史性的高位,交易员们可能正在努力平仓。” 他补充说,巴西创纪录的丰收让市场参与者认为中国不需要购买美国大豆。“然而,不能排除下个月的会议上达成某种协议的可能性,就全球大豆需求而言,这是目前市场前景中最关键的事件。” 周一,美国农业部发布的每周出口检验报告显示,截至4月23日当周,大豆预订量总计2310万蒲式耳。2025/26年度的总检验量目前为12.06亿蒲式耳,比上年下降20%。 美国农业部预计,2025/26年度大豆出口总量将达到15.4亿吨,比上年下降18%。尽管美国农业部对大豆期末库存的估计比过去五年平均水平高出20%,但大豆检验进度仍落后于农业部的预期。
Related Articles
Ora Banda Mining Appoints Chair-elect
Ora Banda Mining (ASX:OBM) has appointed John Richards as chair-elect, with plans for him to assume the role following the retirement of current Chair Peter Mansell at the company's annual general meeting in November, according to a Tuesday filing with the Australian bourse.Richards is currently non-executive chair of Sandfire Resources (ASX:SFR) and lead independent non-executive director of Sheffield Resources (ASX:SFX), the filing added.
Research Alert: Universal Health Services: Q1 Eps Tops Estimates
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:UHS delivered solid Q1 results, with adjusted EPS of $5.62 (up 16.1% Y/Y), $0.16 above consensus, while revenue grew 9.6% to $4.495B due to higher prices despite modest patient volumes. Same-facility acute care revenue increased 8.2% on flat adjusted admissions but 6.3% growth in revenue per admission, while behavioral health saw 1.2% admission growth and 7.3% revenue growth. We think the $835M Talkspace acquisition may expand UHS's virtual behavioral health capabilities and broaden payor mix. Management expects the deal to close in Q3. Operating cash flow improved 11.7% to $402M, and UHS repurchased $127.3M in stock, though adjusted EBITDA margin compressed 20 bps to 14.4% on higher operating expenses. We think behavioral health staffing challenges persist but expect the Talkspace integration to create growth opportunities.
Research Alert: Cls Q1: Blistering Fy 26 Guidance And Cpo Win Tempered By Capital Demands
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Q1 revenues of $4.05B (+53%) and adjusted EPS of $2.16 (+80%) both exceeded guidance on accelerating hyperscaler demand. Adjusted operating margin reached a record 8.0%, due to higher-value CCS offerings, which grew 76% to $3.24B, with segment margin expanding to 8.6%. The company secured a new CPO switch program with a hyperscaler customer expected to ramp in 2027, and we expect more color tomorrow. Management raised 2026 guidance to $19.0B revenue (from $17.0B) and $10.15 adjusted EPS (from $8.75), representing over $6.5B in revenue growth. Stronger growth is anticipated for 2027 based on improved customer visibility and new program wins. The company enlarged its balance sheet by upsizing its credit facility to $2.5B, with revolver capacity increased to $1.75B. FCF of $137.9M remained robust despite elevated capex of $218.4M to support capacity expansion. Share buybacks slowing, FCF guidance lagging, and a +50% month may be contributing to the after-hours selloff.